Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells
Molecules · 2023
DOI: 10.3390/molecules28217342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Thidarath Rattanaburee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Prince of Songkla University, Prince of Songkla University, Songkhla and the Agricultural Research Development Agency, RSU Research Institute of Rangsit University, Thailand.
Abstract (Originalsprache)
This research aimed to determine the target protein and molecular mechanism of trans-(±)-kusunokinin (KU) derivatives ((±)-arctigenin (ARC) and trans-(±)-TTPG-B). Molecular docking was used to predict potential synthesized (±)-KU targets among 22 proteins. The (+)-TTPG-B bound HSP90α better than EC44, native (±)-KU and trans-(±)-ARC. In contrast, (−)-ARC bound PI3K more strongly than any other test compound. CSF1R and AKR1B1 were not supposed to be the target of (±)-TTPG-B and (±)-ARC, unlike native (±)-KU. The (+)-TTPG-B bound Tyr139 and Trp162 of HSP90α. Moreover, (−)-ARC bound PI3K via hydrogen bonds and π-π stacking at distinct amino acids, which was different from the other tested compounds. Using half of the IC50 concentration, (±)-TTPG-B, (±)-KU and (±)-ARC enhanced cell cycle arrest at the G0/G1 phase after 12 h and 24 h on KKU-M213 (CCA) cells. The (±)-TTPG-B showed a stronger inhibitory effect than (±)-ARC and (±)-KU on HSP90α, PI3K, HSP90β, c-Myc, AKT, MEK1, CyclinB1, CyclinD1, and CDK1 for 24 and 48 h after treatment with the same concentration (0.015 µM). Thus, trans-(±)-TTPG-B, a newly synthesized compound, has pharmacological potential for development as a target therapy for CCA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
- Biochemistry Unit, Department of Medical Sciences, Faculty of Science, Rangsit University, Pathum Thani 12000, Thailand.
- Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
ORCID-Profile: Thidarath Rattanaburee, Varomyalin Tipmanee, Potchanapond Graidist
Förderung
- Faculty of Medicine, Prince of Songkla University
- Prince of Songkla University, Songkhla and the Agricultural Research Development Agency
- RSU Research Institute of Rangsit University, Thailand
- Prince of Songkla University
- RSU Research Institute of Rangsit University
Zitieren
APA
Rattanaburee, T., Chompunud Na Ayudhya, C., Thongpanchang, T., Tipmanee, V., & Graidist, P. (2023). Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells. Molecules. https://doi.org/10.3390/molecules28217342
Vancouver
Rattanaburee T, Chompunud Na Ayudhya C, Thongpanchang T, Tipmanee V, Graidist P. Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells. Molecules. 2023. doi:10.3390/molecules28217342
BibTeX
@article{Rattanaburee2023,
author = {Rattanaburee, Thidarath and Chompunud Na Ayudhya, Chompunud and Thongpanchang, Tienthong and Tipmanee, Varomyalin and Graidist, Potchanapond},
title = {Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28217342}
}
EUVIMED